JNJ
NYSEJOHNSON & JOHNSON
Health Care, Pharmaceuticals
$259.24
close 7 Aug 2026
+49.14%
52-week change
$624.74B
market cap
$171.81
$274.90
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||||
| Revenue | $97.93B | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | $71.31B | $67.22B | $65.03B | $61.59B | $61.90B | $63.75B | $61.10B |
| Cost of revenue | $31.43B | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B | $21.54B | $22.75B | $22.34B | $21.66B | $20.36B | $18.79B | $18.45B | $18.51B | $17.75B |
| Gross profit | $66.50B | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.80B | $43.45B | $45.24B | $43.34B |
| R&D | $548.00M | $109.00M | $1.84B | $483.00M | $0.00 | $0.00 | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B |
| SG&A | $25.14B | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B | $21.20B | $21.95B | $21.83B | $20.87B | $20.97B | $19.42B | $19.80B | $21.49B | $20.45B |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.70B | $16.58B | — | — |
| Interest expense | $1.01B | $971.00M | $755.00M | $772.00M | $276.00M | $183.00M | $201.00M | $318.00M | $1.01B | $934.00M | $726.00M | $552.00M | $533.00M | $482.00M | $532.00M | $571.00M | $455.00M | $451.00M | $435.00M | $296.00M |
| Tax expense | $4.16B | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.70B | $16.37B | $3.26B | $3.79B | $4.24B | $1.64B | $3.26B | $2.69B | $3.61B | $3.49B | $3.98B | $2.71B |
| Net income | $21.04B | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B |
| Diluted EPS | $8.61 | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.4700 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
| Gross margin | 67.91% | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | — | 29.05% | 23.01% | 22.25% | 21.17% | 28.74% | 26.79% | — | — |
| Net margin | 21.48% | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% |
filed 23 Jul 2026